Abstract
Introduction: The possibilities of forming effective regimes of chemotherapy when exists XDR of MBT culture are significantly restricted. The experience of using such drugs as linezolid and bedaquiline in present time is not enough.
Aims: Estimate effectiveness and safety of six monthpolychemotherapy course including bedaquiline and linezolid.
Methods: We performed a prospective nonrandomized multicenter investigation. There were 32 patients(9 m/23 f) with XDR TB, the age of patients varying There were 12,5% of firstly revealed patients and 87,5% of patients after previous ineffective therapy. 12,5% of patients had length of disease less than 1 year, 68% of patients had length of disease from 1 to 3 years and 19,5% of patients had length of disease more than 3 years. All patients, included in investigation had MBT+ in their sputum. All the patients had cavitary lesions in lung tissue and 65,6% of patients had double lung lesions. Six month chemotherapy course included 4 drugs of first or second line according to susceptibility in combination with bedaquiline and linezolid.
Results: It was 31(96,9%) patients who finished 24 weeks course. Among them 83,9% of patients became MBT negative; 77,4% of patients had significant positive X-ray dynamics; 43,7% had closure of cavitary lesions. 7(22,6%) patients were successfully prepared for surgery and were operated later. We had 1 side effect – enlargement of QT-interval more than 520 ms, this patient was exclude from investigation.
Conclusions: Including of bedaquiline and linezolid combination in complex therapy of XDR TB is highly effective and well tolerated by patients.
- Copyright ©the authors 2016